AstraZeneca PLC (GB:AZN)
LSE:AZN
AZN Stock Chart & Stats
15316.00 p
84.00 p(0.78%)
At close: 4:00 PM EST
15316.00 p
84.00 p(0.78%)
Day’s Range― - ―
52-Week Range9,573.51 p - 15,554.00 p
Previous CloseN/A
Volume91.53K
Average Volume (3M)2.23M
Market Cap
£237.53B
Enterprise Value337.42B
Total Cash (Recent Filing)£5.74B
Total Debt (Recent Filing)£29.62B
Price to Earnings (P/E)28.1
Beta1.11
Next Earnings
Apr 29, 2026EPS Estimate
1.91Next Dividend Ex-DateN/A
Dividend Yield1.53%
Share Statistics
EPS (TTM)1.60
Shares Outstanding1,550,980,800
10 Day Avg. Volume2,301,712
30 Day Avg. Volume2,229,651
Financial Highlights & Ratios
PEG Ratio0.58
Price to Book (P/B)5.91
Price to Sales (P/S)4.90
P/FCF Ratio33.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£16,364.27Price Target Upside6.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)10.28
Revenue Forecast (FY)£63.07B
Bulls Say, Bears Say
Bulls Say
Broad Late Stage PipelineAnalyst notes a broad late stage pipeline with a concentrated slate of upcoming clinical readouts and potential launches that could materially re rate the stock if results remain favorable.
Commercial Prescription GrowthAnalyst points to strong prescription growth across several key marketed medicines that supports sales momentum and could enhance operating margins through leverage in selling and administrative spending.
Tozorakimab Clinical SuccessAnalyst highlights Phase three success for tozorakimab showing clinically meaningful reductions in moderate to severe chronic obstructive pulmonary disease exacerbations across former and current smokers, de risking a potential multi blockbuster commercial opportunity.
Bears Say
Pricing And Value Based PaymentsAnalyst warns that mandatory price reductions and stock compensation tied to value based pricing for select medicines could put meaningful pressure on profitability.
Research Objectivity ConcernsAnalyst notes that business relationships between some research firms and covered companies may create potential conflicts of interest that could cloud the objectivity of published reports and hamper investor clarity.
Study Timing UncertaintyAnalyst highlights study delays driven by slower event rates that introduce uncertainty around the timing of key trial readouts and reduce visibility for development milestones.
AstraZeneca News
AZN FAQ
What was AstraZeneca PLC’s price range in the past 12 months?
AstraZeneca PLC lowest share price was 9573.50 p and its highest was 15554.00 p in the past 12 months.
What is AstraZeneca PLC’s market cap?
AstraZeneca PLC’s market cap is £237.53B.
When is AstraZeneca PLC’s upcoming earnings report date?
AstraZeneca PLC’s upcoming earnings report date is Apr 29, 2026 which is in 23 days.
How were AstraZeneca PLC’s earnings last quarter?
AstraZeneca PLC released its earnings results on Feb 10, 2026. The company reported 1.604 p earnings per share for the quarter, beating the consensus estimate of 1.581 p by 0.023 p.
Is AstraZeneca PLC overvalued?
According to Wall Street analysts AstraZeneca PLC’s price is currently Undervalued.
Does AstraZeneca PLC pay dividends?
AstraZeneca PLC pays a Semiannually dividend of 76.7 p which represents an annual dividend yield of 1.53%. See more information on AstraZeneca PLC dividends here
What is AstraZeneca PLC’s EPS estimate?
AstraZeneca PLC’s EPS estimate is 1.91.
How many shares outstanding does AstraZeneca PLC have?
AstraZeneca PLC has 1,550,980,800 shares outstanding.
What happened to AstraZeneca PLC’s price movement after its last earnings report?
AstraZeneca PLC reported an EPS of 1.604 p in its last earnings report, beating expectations of 1.581 p. Following the earnings report the stock price went up 1.987%.
Which hedge fund is a major shareholder of AstraZeneca PLC?
Currently, no hedge funds are holding shares in GB:AZN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AstraZeneca Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
£16,364.27 (6.84% Upside)
£16,364.27 (6.84% Upside)
Blogger Sentiment
Bullish
GB:AZN Sentiment 75%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.70%
12-Months-Change
Fundamentals
Return on Equity
23.00%
Trailing 12-Months
Asset Growth
2.10%
Trailing 12-Months
Company Description
AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
AZN Stock 12 Month Forecast
Average Price Target
16,364.27 p
▲(6.84% Upside)
Technical Analysis
ConvaTec
―
GlaxoSmithKline
―
Hikma Pharmaceuticals
―
Smith & Nephew
―
Beximco Pharmaceuticals Limited Sponsored GDR RegS
―
Options Prices
Currently, No data available
---